

Bone Morphogenetic Protein-9 Is a Potent Chondrogenic and Morphogenic Factor for Articular Cartilage Chondroprogenitors

Ben J. Morgan,¹ Guillermo Bauza-Mayol,¹ Oliver F. W. Gardner,^{1,2} Yadan Zhang,¹ Riccardo Levato,³ Charles W. Archer,¹ Rene van Weeren,⁴ Jos Malda,^{3,4} Robert Steven Conlan,¹ Lewis W. Francis,¹ and Ilyas M. Khan¹

Articular cartilage contains a subpopulation of tissue-specific progenitors that are an ideal cell type for cell therapies and generating neocartilage for tissue engineering applications. However, it is unclear whether the standard chondrogenic medium using transforming growth factor beta (TGF β) isoforms is optimal to differentiate these cells. We therefore used pellet culture to screen progenitors from immature bovine articular cartilage with a number of chondrogenic factors and discovered that bone morphogenetic protein-9 (BMP9) precociously induces their differentiation. This difference was apparent with toluidine blue staining and confirmed by biochemical and transcriptional analyses with BMP9-treated progenitors exhibiting 11-fold and 5-fold greater aggrecan and collagen type II (COL2A1) gene expression than TGF β 1-treated progenitors. Quantitative gene expression analysis over 14 days highlighted the rapid and phased nature of BMP9-induced chondrogenesis with sequential activation of aggrecan then collagen type II, and negligible collagen type X gene expression. The extracellular matrix of TGF β 1-treated progenitors analyzed using atomic force microscopy was fibrillar and stiff whilst BMP9-induced matrix of cells more compliant and correspondingly less fibrillar. Polarized light microscopy revealed an annular pattern of collagen fibril deposition typified by TGF β 1-treated pellets, whereas BMP9-treated pellets displayed a birefringence pattern that was more anisotropic. Remarkably, differentiated immature chondrocytes incubated as high-density cultures in vitro with BMP9 generated a pronounced anisotropic organization of collagen fibrils indistinguishable from mature adult articular cartilage, with cells in deeper zones arranged in columnar manner. This contrasted with cells grown with TGF β 1, where a concentric pattern of collagen fibrils was visualized within tissue pellets. In summary, BMP9 is a potent chondrogenic factor for articular cartilage progenitors and is also capable of inducing morphogenesis of adult-like cartilage, a highly desirable attribute for in vitro tissue-engineered cartilage.

Keywords: chondroprogenitors, BMP9, GDF2, anisotropic, differentiation, cartilage

Introduction

STEM CELL THERAPIES have been used in numerous studies in attempts to repair cartilage lesions, but thus far, no solution has been able to regenerate the full adult structure of this tissue [1]. The most obvious route to successful cell therapies lies in understanding and mimicking endogenous growth and developmental processes, either to grow cartilage in vitro or endow implanted cells with sufficient cues to differentiate and develop functional repair tissue. Central to

achieve these objectives is the use of progenitor cells receptive to specific instructive cues as well as the use of well-defined differentiation factors to drive the generation of neocartilage [2,3].

Cartilage lesions are a common occurrence during exploratory knee arthroscopic surgery with a reported prevalence of 65% [4]. If these lesions are not repaired they may over time progress to diffuse osteoarthritis [5]. Their treatment remains difficult because intrinsic repair mechanisms are inadequate mainly due to the avascular nature of

¹Centre of Nanohealth, Swansea University Medical School, Swansea, United Kingdom.

²Stem Cells and Regenerative Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

³Department of Orthopaedics, University Medical Center Utrecht, Utrecht, the Netherlands.

⁴Department of Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

cartilage tissue and the inability of resident chondrocytes to mobilize and direct repair [6,7]. Cell transplantation and subchondral bone stimulation [8] have been developed to repair localized lesions [9], but crucially neither technique can significantly reduce the medium and long-term risk of patients developing osteoarthritis [10,11]. In a 15-year follow-up study, Knutsen et al. found that 57% of patients treated with cell transplantation and 48% of patients treated by microfracture had radiographic signs of early osteoarthritis [11].

In contrast, osteochondral allografting is a highly effective surgical technique to repair large >2 cm² cartilage defects in synovial joints [12,13]. Cartilage and adjoining bone from donors are transplanted to areas in recipients requiring resurfacing with the aim of restoring normal joint function. The principal advantages of allotransplantation are the use of structurally intact hyaline cartilage and bone with no concurrent morbidity as would be the case for autografting. Clinical studies using cartilage allografts have showed favorable outcomes, with graft survival as high as 95% at 5 years and 85% at 10 years [14]. The limitations of allografting are the availability and storage of donor cartilage, with storage beyond 21 days causing a significant reduction in cellular viability that impact graft quality and survival [15]. Tissue engineering has the potential to fulfill the increasing demand for allografts through the use of expandable cell sources capable of maintaining chondrogenic potency to generate functional hyaline neocartilage.

Donor chondrocytes from recipients cannot be used to repair larger cartilage defects because they undergo dedifferentiation and progressively lose the capacity to redifferentiate after 4–5 population doublings [16]. Consequently, the size of cartilage lesions that can be repaired, typically requiring concentrations of several million cells per cm², is also limited [17]. To overcome this hurdle, adult mesenchymal stem cells (MSCs) such as bone marrow-derived stromal cells with the capacity to undergo chondrogenic differentiation have been used for cell therapy either by autologous implantation into defects [18] or through marrow stimulation through drilling the subchondral bone plate [8]. Marrow-derived MSCs generate a transient fibrocartilagenous template with biomechanical deficits that compromise cell survival in the adult joint [19]. More detailed examination of marrow-derived MSC function suggests that their therapeutic effects are mediated through paracrine effects on recruited cells or coimplanted chondrocytes [20,21]. Therefore, the discovery of tissue-specific progenitor-like cells in articular cartilage with the ability to generate the cell numbers required for cell therapies and tissue engineering is of great significance [22,23].

Articular cartilage-derived chondroprogenitors were first detected as bromodeoxyuridine label retaining cells in the superficial zone of fetal marsupial articular cartilage [23,24]. Subsequently, cells with colony-forming ability were isolated from postnatal immature bovine cartilage that fulfilled the minimal requirements to be classified as mesenchymal progenitors; exhibiting plastic adherence, CD90⁺, CD105⁺, CD73⁺, CD166⁺, CD34⁻, and CD45⁻ antibody reactivity, multipotential phenotypic plasticity, and the ability to home joint tissues [22,25]. Articular cartilage-derived chondroprogenitors maintain sex determining region Y-box 9 (SOX9) expression and telomere length following extensive culture expansion, accounting for their ability to undergo chondrogenic redifferentiation following more than 30

population doublings [26]. Critically, studies have found runt-related transcription factor-2 (RUNX2) and collagen type X, markers of terminally differentiated epiphyseal chondrocytes are absent or expressed at negligible levels in articular chondroprogenitors, restricting their differentiation to the production of hyaline-like cartilage [27].

Defining the optimal pathways for chondrogenic differentiation and organized extracellular matrix production of tissue specific chondroprogenitors is therefore an important objective for tissue engineering cartilage and developing effective cell therapies. While chondrogenesis of epiphyseal chondroblasts and MSCs has been extensively described, and shown to be induced in medium containing transforming growth factor beta-1 (TGFβ1), dexamethasone, ascorbate, and insulin [28], there have been no comparable studies to determine the optimal chondrogenic medium for articular chondroprogenitors. TGFβ stimulates chondrogenesis in articular progenitors, although cartilage production is principally confined to the periphery of high-density pellet cultures, indicating a lack of potency [26].

The unique developmental history of articular chondroprogenitors led us to hypothesize that there are more potent chondrogenic factors for this cell type. Therefore, to determine the optimal chondrogenic medium for articular chondroprogenitors, we screened cells against a panel of known chondrogenic factors using high-density pellet culture as a means to analyze their potency.

Materials and Methods

Chondroprogenitor isolation

Articular cartilage tissue was harvested from freshly obtained healthy bovine metacarpophalangeal (MCP) joints (Cig Calon Cymru). Swansea University is registered for use of animal by-products as required under the requirements of Article 23 (EC) No. 1069/2009, and the work carried out in this study using these products was following institutional approval. Cartilage was removed from MCP joints of immature 7-day-old steers under sterile conditions and washed in Dulbecco's modified Eagle's medium (DMEM; Gibco) before sequential digestion with pronase (Roche) at 70 U/mL (0.2% w/v) in DMEM for 2 h, with the solution decanted and then medium added containing DMEM, 10 mM HEPES pH 7.4, 50 µg/mL gentamicin, 1% fetal bovine serum (FBS) with collagenase from *Clostridium histolyticum* (Sigma) at 300 CDU/mL (0.04% w/v) for 16 h, using a tube rotator or roller (Miltenyi Biotec) at 37°C and 5% CO₂. Tissue digests were passed through a gravity driven nylon 40 µm cell strainer (Corning) to generate a single cell suspension.

Chondroprogenitor isolation was performed by differential adhesion of chondrocytes to plastic six-well plates (Greiner) that were precoated with 10 µg/mL of fibronectin (0.1% solution from bovine plasma; Sigma) in phosphate-buffered saline (PBS, pH 7.4) with 1 mM MgCl₂ and 1 mM CaCl₂ for 24 h at 4°C. Approximately 1,000 cells per well in 1.5 mL DMEM were incubated for 20 min on the fibronectin-coated plates at 37°C in a CO₂ incubator, after which, nonadherent cells were removed and 3 mL of standard culture medium, DMEM (1 g/L glucose), 50 µg/mL ascorbic acid-2-phosphate, 10 mM HEPES pH 7.4, 1 mM sodium pyruvate, 2 mM L-glutamine, and 10% FBS and 50 µg/mL gentamicin added to each well.

After 6 days of culture, well-spaced cell colonies of more than 32 cells, therefore excluding transit-amplifying cells, were isolated using sterile cloning rings (Sigma) using trypsin/ethylenediaminetetraacetic acid (EDTA) and transferred to six-well plates for culture expansion in standard culture medium. Unexpanded freshly isolated full-depth chondrocytes used for differentiation assays using the same basal chondrogenic medium as described below were from the same source and used following tissue digestion and cell straining.

Chondroprogenitor differentiation

Basal medium for chondrogenic differentiation was composed of DMEM/F12 nutrient mix (1:1 with GlutaMAX, 17.25 µg/L L-proline, 3.151 g/L glucose; Cat. No. 31331-028; Gibco), supplemented with 10% heat-inactivated (60°C for 45 min) FBS, 100 µg/mL L-ascorbic acid 2-phosphate, 1% insulin-transferrin-selenium (ITS-X; Thermo Fisher Scientific), 10 mM HEPES pH 7.4, and 50 µg/mL gentamicin. Chondrogenic factors used in this study are listed with the final concentration used in pellet culture shown in brackets; chelerythrine chloride (CCI), a cell-permeable inhibitor of protein kinase C (0.66 µM), dibutyryl-cAMP (db-cAMP) a cell-permeable cyclic AMP analog that activates cAMP-dependent protein kinases (0.5 mM; Bio-Techne Ltd.), concanavalin A from *Canavalia ensiformis* (3 µg/mL), C-natriuretic peptide (CNP; 0.1 µM), ethanol (1.5% v/v; all Sigma-Aldrich), TGFβ1/2/3 (10 ng/mL), and bone morphogenetic protein (BMP) 2/9 (100 ng/mL; all PeproTech EC, Ltd.). For three-dimensional pellet culture, individual chondroprogenitor clones between 22 and 27 population doublings cells were trypsinized and 5×10^5 cells were added to a sterile Eppendorf tubes in 1000 µL basal chondrogenic medium. The cell suspension was then centrifuged at 315 g for 5 min at room temperature to enable pellet formation, then incubated at 37°C and 5% CO₂. After 24 h, cell pellets were gently aspirated with surrounding medium from the Eppendorf surface using a pipette to facilitate pellet rounding. Pellets were incubated with fresh medium every 72 h until the end of the culture period [29]. For differentiation on two-dimensional plastic, individual chondroprogenitor lines were seeded onto six-well dishes at a concentration of 1×10^5 cells per well in standard culture medium. Each culture plate was then incubated at 37°C and 5% CO₂ until the well was 80% confluent, upon which the medium was aspirated and 3 mL of prewarmed chondrogenic medium with or without growth factor added. The plate was then incubated at 37°C and 5% CO₂ and medium changed once until analysis at 4 days posttreatment.

RNA extraction

Pellets. Stored frozen pellets were thawed and lysis buffer RLT added (RNeasy kit; Qiagen). Pellets were then mechanically homogenized for 30 s using a TissueRuptor device (Qiagen) using sterile probes. Total RNA was extracted using RNeasy columns with a DNase1 on-column digest as per manufacturer's instructions.

Reverse transcription-quantitative polymerase chain reaction. Complementary DNA (cDNA) was synthesized using ~100 ng total RNA using standard methods. Quantitative polymerase chain reaction (qPCR) was performed using a Bio-Rad CFX96 thermal cycler using 25 µL reaction volumes

in 96-well plates (Bio-Rad). Each reaction contained 3.5 mM MgCl₂, 200 µM dNTPs, 0.3 µM forward and reverse primers, 0.025 U/µL Taq polymerase, and SYBR Green (GoTaq qPCR Master mix; Promega) with programmed reaction conditions of 1 cycle of 95°C for 10 min, 40 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 1 min, and 1 cycle of 72°C for 5 min and then 4°C. Absolute values for gene expression were calculated from standard curves generated using cloned and sequence-verified, serially diluted, plasmid template DNA. Primer sequences used for reverse transcription-qPCR have been previously published [30–32].

Biochemical compositional analysis

Before biochemical analyses, frozen cell pellets were thawed and solubilized by incubation in papain digestion buffer (20 mM NaAc pH 6.8, 1 mM EDTA pH 8.0, 2 mM dithiothreitol, and 300 µg/mL papain from *Papaya latex*; Sigma) at 60°C for 1 h. The Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific) was used to measure DNA content using 50 µL volume of papain digested pellet according to the manufacturer's protocol and measured using a FLUOstar Omega plate reader (BMG Labtech). Data were compared to a linear standard curve (0–20 µg/mL) made using calf thymus DNA. To calculate cell number, DNA values were divided by 7.7 pg, the approximate weight of the bovine genome [33]. For sulfated glycosaminoglycan (sGAG) measurements, 20 µL of papain digested pellet sample was added to 200 µL of DMMB reagent (16 mg/L dimethylmethylene blue, 3 g polyvinyl alcohol 30–70 kDa, 3.04 g glycine, 2.37 g NaCl, and 95 mL 0.1 M HCl) in a 96-well plate before shaking for 5 s. The concentration of sGAG in each sample was determined by spectrophotometric measurement of absorbance at 525 nm and compared against a standard curve of shark chondroitin-4-sulphate (0–40 µg/mL; Sigma). Collagen content in pellets was determined using an assay to measure hydroxyproline in papain digested samples and comparing values against a standard curve of hydroxyproline (0–100 µg/mL).

Histological analysis

Cell pellets were washed with PBS then fixed in 10% neutral buffered formal saline (NBFS) for 12 h at 4°C, then processed for wax embedding. sGAG deposition was observed by using the metachromatic dye toluidine blue at 1% aqueous concentration for 60 s. To visualize collagen content and fibril alignment, rehydrated sections were stained in 0.1% w/v picrosirius red in saturated picric acid for 30 min.

Immunohistochemistry

Formalin-fixed paraffin-embedded samples were sectioned to a thickness of 5 µm before immunohistochemical labeling. Sections were dewaxed in Histo-Clear (National Diagnostics) and rehydrated through an ethanol gradient before being brought to deionized water. Antigen retrieval was performed in two stages; an overnight incubation at 65°C in a pH 9 10 mM Tris, 1 mM EDTA, 0.05% Tween-20 buffer solution, followed by incubation with 1 mg/mL hyaluronidase (bovine testes; Sigma) in phosphate-buffered saline (PBS) buffer at 37°C for 1 h. Sections were blocked using horse serum (2.5%; Vector Laboratories) for 30 min. Labeling was performed against

aggrecan [1-C-6, Developmental Studies Hybridoma Bank (DSHB)], collagen type I (C2456; Sigma), and collagen type II (II6B3, DSHB). Primary antibodies were diluted 1:10 for aggrecan and collagen type II and 1:2,000 for collagen type I, in PBS Tween-20 (0.05%). Primary antibody detection was performed using the RTU biotinylated pan-specific antibody, RTU streptavidin/oxidase complex and ImmPACT NovaRED Peroxidase Substrate (Vector Laboratories), according to manufacturers' instructions. Sections were counterstained with Meyer's hematoxylin (TCS Biosciences) and mounted using DPX Mounting Medium (Electron Microscopy Sciences).

Atomic force microscopy

Chondrogenitor cell monolayer cultures were imaged and analyzed using quantitative nanomechanical mapping (QNM) and force volume (FV) to assess changes in morphological and nanomechanical phenotype between the different populations at expansion stage and under differentiation conditions. Imaging experiments were performed using a Bioscope Catalyst (Bruker) instrument in either QNM or FV mode. High aspect ratio silicon probes, MLCT-D (Bruker), were used for the experiments with a spring constant of 0.03 N/m and a cantilever calibrated using in house manufacturer protocols before each experiment. Cells were imaged alive in DMEM without phenol red (Gibco) media, at 37°C. Care was taken to avoid the generation of imaging artefacts throughout. At least 6 cells per sample were analyzed taking 25 FV curves per cell in a 2.5 μm^2 area in 30 min not to lose the phenotype or adherence of the cells. A 1 μm ramp size was applied to the sample with a force of 500 pN, the ramp rate was 1.03 Hz with constant forward and reverse tip velocity of 2.06 $\mu\text{m}/\text{s}$. When imaging in QNM mode, peak force amplitude and frequency were set at 500 nm and 0.25 kHz, respectively. The scan rate was 0.5 Hz and the 5.05 $\mu\text{m}/\text{s}$ tip velocity, applying a force between 1 and 0.5 nN with feedback gain of 1.000.

Statistical analyses

All statistical approaches were performed using SPSS software version 19.0 for the windows operating system. All

data sets were first analyzed for normality using the Anderson Darling test. Statistical significance was calculated using one-way analysis of variance. Post hoc analysis was performed using Tukey's honestly significant difference method. All statistical significance threshold values are $P < 0.05$, unless otherwise stated in the text.

Results

Articular cartilage progenitors from immature cartilage were cultured as high-density cell pellets for 21 days in the presence of minimal chondrogenic culture medium that was supplemented with previously characterized chondrogenic factors, TGF β 1–3 (10 ng/mL), BMP 2/9 (100 ng/mL), dexamethasone (Dex), CNP, db-cAMP, concavalin-A (ConA), ethanol (EtOH), and CCl at concentrations previously shown to induce differentiation in receptive mesenchymal cells [34–43]. Histologic examination of toluidine blue-stained sections of cartilage pellets showed an increasing gradation in size and staining intensity from ethanol to BMP9-treated chondrogenitors (Fig. 1). Only BMP9-treated chondrogenitors showed uniform deep purple toluidine blue staining throughout the pellet depth, with the other factors showing variegated staining of pellets due either to the lack of sulfated proteoglycan or to the metachromatic nature of the dye, where reduced staining is visualized as a blue color.

Quantification of sGAG content using the DMMB assay normalized to DNA content revealed a 6-fold increase in sGAG in BMP9 pellets compared to minimal medium alone ($P < 0.01$) and 2.3-fold greater accumulation of sGAG than TGF β 1-treated pellets ($P < 0.01$) (Fig. 2A). Other than BMP9, only dexamethasone 2.4-fold, TGF β 1 2.8-fold, and db-cAMP 3.3-fold showed significantly increased sGAG content ($P < 0.01$) compared to pellets cultured in minimal medium. When hydroxyproline content was measured in pellets, TGF β 2 3.4-fold, TGF β 3 3.4-fold, db-cAMP 5.8-fold, TGF β 1 7.8-fold, and BMP9 11.5-fold-treated pellets showed a greater deposition of collagen compared to pellets cultured in minimal medium ($P < 0.01$) (Fig. 2B). Analysis of aggrecan (ACAN) and collagen type II (COL2A1) gene




FIG. 1. Toluidine blue-stained sections of chondrogenitor pellets grown as high-density pellet cultures. Pellets of 5×10^5 cells were grown in minimal chondrogenic medium (Con) or supplemented with EtOH, CCl, ConA, CNP, BMP2/9, TGF β 1–3, dexamethasone (Dex), and dc-AMP. Pellets are ordered according to the quantity of sGAG normalized to DNA content (Fig. 2A). Representative images of three independent experiments. Scale bar equals 500 μm . BMP, bone morphogenetic protein; CCl, chelerythrine chloride; CNP, C-natriuretic peptide; ConA, concavalin-A; dc-AMP, dibutyl cyclic adenosine monophosphate; EtOH, ethanol; sGAG, sulfated glycosaminoglycan; TGF β , transforming growth factor beta. Color images are available online.





FIG. 2. Quantification of (A) sGAG ($n=6$), (B) hydroxyproline content ($n=6$), and gene expression levels of (C) ACAN and (D) COL2A1 in chondrogenitor pellet cultures ($n=4$ for both genes). (E) Selected pellets were screened for reactivity against antibodies to collagen (Col) types I and II and aggrecan (Agg). Scale bar equals 100 µm. * $P<0.05$, ** $P<0.01$ versus control. ACAN, aggrecan; COL2A1, collagen type II. Color images are available online.

expression in pellets led to broadly similar changes with BMP9 pellets showing 33-fold greater ACAN gene expression compared to pellets in minimal medium ($P<0.01$) and 10.6-fold more than in TGFβ1 pellets ($P<0.01$) (Fig. 2C). COL2A1 gene expression was similarly 17-fold

higher in BMP9 compared to minimal medium pellets ($P<0.01$) and 5.4-fold higher than TGFβ1 pellets ($P<0.01$) (Fig. 2D). Of note, the greatest contrast between biochemical content and gene expression measurements were for ethanol-treated pellets, where gene expression values for

FIG. 3. Cellular content of cultured chondroprogenitor pellets cultured in minimal chondrogenic medium, or the same medium supplemented with various chondrogenic factors. **(A)** Cell number ($n=6$) was calculated by dividing total DNA content of papain digested pellets by the approximated weight of DNA in a single bovine chondrocyte (calculated as 7.7 pg [33]). Gene expression analysis using qPCR of **(B)** PCNA and **(C)** NES in chondroprogenitor pellets ($n=4$ for both genes). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus control. NES, nestin; PCNA, proliferating cell nuclear antigen; qPCR, quantitative polymerase chain reaction.



ACAN and COL2A1 were among the highest, while the content values for proteoglycan (sGAG) and collagen (hydroxyproline) normalized to DNA were the lowest.

Immunohistochemical labeling of sections from pellets cultured in minimal chondrogenic medium, or supplemented with TGF β 1, BMP9, db-cAMP, or ethanol, against antibodies labeling collagen types I and II, and aggrecan illustrated not only the differences in relative amount of protein deposited in the extracellular matrix of pellets but also their differential localization (Fig. 2E). BMP9-treated pellets displayed labeling for collagen type II and aggrecan throughout the full depth of the pellet, whereas TGF β 1-treated pellets had higher collagen type I labeling throughout the pellet with aggrecan labeling concentrated at the pellet periphery as predicted from toluidine blue staining (Fig. 1).

The DNA content of chondroprogenitor pellets, converted to cell number, had two interesting features; first, BMP9 pellets exhibited the smallest average increase in cell number from the starting count of 5×10^5 cells (26%), this was 2.6-fold less than average cell counts for pellets cultured in minimal medium ($P < 0.01$). Second, CNP, CCI, and ethanol-treated pellets exhibited significant increases in cell number when compared to pellets cultured in minimal medium alone ($P < 0.01$) (Fig. 3A). Gene expression analysis using primers for proliferating cell nuclear antigen (PCNA) correlated with DNA measurements showing increased cell number most notably in ethanol-treated pellets ($P < 0.01$) (Fig. 3B). qPCR analysis also showed that nestin (NES), a marker for MSCs, was significantly increased in ethanol treated pellets only compared to pellets in minimal chondrogenic medium. Analysis of the relationship between DNA and proteoglycan content of pellets showed a strong negative correlation ($r = -0.88$, $P < 0.001$) between the two variables with sGAG content decreasing with increasing DNA content.

Titration of BMP9 growth factor to determine the optimum concentration for articular chondroprogenitor differentiation was examined in the range of 0–200 ng/mL of growth factor using gene expression analysis of ACAN,

COL2A1, and collagen type X (COL10A1) of cells grown in monolayer (Fig. 4). These data show that 100 ng/mL BMP9 was the optimum concentration for chondrogenic induction of progenitors, ACAN and COL2A1 gene expression was highest at this concentration ($P < 0.001$), whereas COL10A1 gene expression was greatest using BMP9 at 200 ng/mL. While COL10A1 levels at 100 ng/mL BMP9 also induced a significant increase, they were 7-fold less than using the highest BMP9 concentration ($1.4 \times 10^{-3} \pm 1 \times 10^{-4}$ vs. $9.7 \times 10^{-3} \pm 4 \times 10^{-4}$); in absolute terms, the expression level of COL10A1 was ~ 450 -fold less than COL2A1 gene expression levels (0.68 ± 0.01) at the same concentration of BMP9 (100 ng/mL).

Developmental analysis of chondrogenesis has revealed that extracellular matrix accumulation occurs in a phasic manner. To examine if this was the case with BMP9-treated chondroprogenitors, we measured the change in gene expression of ACAN, COL2A1, and COL10A1 in chondroprogenitor pellets over a period of 14 days. Visual observation of pellet growth in BMP9 supplemented minimal medium indicated that there was rapid growth over the first 7–10 days beyond which point any increase in size was imperceptible (data not shown). Gene expression data collected over a 14-day period and normalized to pellets grown in minimal chondrogenic medium (Fig. 5A) showed that ACAN gene expression was maximal between days 2 and 4 and fell for the remaining period of analysis (day 0 0.35 ± 0.07 , day 3 9.48 ± 2.02 , and day 7 0.93 ± 0.22). Similarly, COL2A1 gene expression peaked between days 6 and 8 (day 0 0.09 ± 0.008 , day 7 3.66 ± 0.53 , day 9 0.87 ± 0.15). The levels of COL10A1 gene transcription did not rise significantly over 14 days and were maximal at day 7 (0.017 ± 0.016) ~ 215 -fold less in absolute terms compared to COL2A1 at day 7. We also examined markers of cellular proliferation, PCNA, and MSC marker, NES, over the same time period (Fig. 5B). We noted that the pattern of gene expression, which was maximal between days 6 and 8, was similar for both PCNA and NES.

Collagen deposition is a critical factor in the extracellular matrix of cartilage tissue, and the manner in which the




FIG. 4. Determining the optimum BMP9 concentration for chondrogenic induction of immature articular chondroprogenitors. Progenitors ($n = 4$) grown in monolayer to near confluence (80%) were exposed to increasing concentration of BMP9 (0–200 ng/mL) for 4 days and then assayed for gene expression using qPCR of (A) ACAN, (B) COL2A1, and (C) COL10A1. * $P < 0.05$, ** $P < 0.01$ versus control. COL10A1, collagen type X.




FIG. 5. Quantitative analysis of gene expression in BMP9-treated chondrogenitor pellets over 14 days. Chondrogenitor pellets ($n=3$) from 9 time points over 14 days were processed to isolate RNA and assayed using RT-qPCR gene expression of (A) COL2A1, ACAN, and COL10A1 and (B) PCNA and NES. RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

collagen fibrils are aligned in the tissue affects their overall contribution to the structure and function of tissue. Using picrosirius red staining and polarized light microscopy (PLM), we observed patterns of birefringence characteristic of collagen fibril alignment in pellet cultures (Fig. 6A). The most striking feature was the parallel alignment of thick fibrils within pellets most notable in TGF β 1-treated chondrogenitors. At lower magnification, some evidence of anisotropic collagen fibril organization could be observed in pellets cultured with CCI, dexamethasone and BMP9. To confirm the differential nature of the extracellular matrix induced by different growth factors, atomic force microscopy (AFM) analysis was to determine the biophysical characteristics of matrix deposited surrounding cells after

TGF β 1 or BMP9 exposure in monolayer culture. These experiments show that cell stiffness increases significantly upon differentiation with both growth factors, but the magnitude of increase is greater using TGF β 1 (Fig. 7A). Topographic maps of the matrix surrounding cells showed more fibrous matrix in TGF β 1-treated chondrogenitors, a feature much less prominent in matrix surrounding BMP9-treated cells (Fig. 6B).

We reasoned that predifferentiated cells, that is, full-depth chondrocytes isolated from intact immature cartilage, and not requiring chondrogenesis before producing extracellular matrix, would allow us to distinguish the different functions of BMP9 on chondrocytes and cartilage. PLM analysis of 21-day pellet cultures of 5×10^5 chondrocytes




FIG. 6. Organization of collagen fibrils in differentiated chondroprogenitor pellets using polarized light microscopy. (A) Pellets grown for 21 days were sectioned and stained with 1% PSR, washed, and mounted using DPX under coverslip. Scale bar equals 100 μm. (B) Atomic force microscopy analysis of the extracellular matrix deposited by chondroprogenitors cultured in monolayer undergoing differentiation following exposure to TGFβ1 and BMP9. Representative images show the fibrillar nature of the matrix produced by TGFβ1-treated progenitors compared to BMP9 cells. (C) Stiffness of the extracellular matrix surrounding chondroprogenitors grown in minimal chondrogenic medium or supplemented with TGFβ1 or BMP9 ($n=4$, $***P<0.001$ vs. control). Representative images from two independent experiments. PSR, picrosirius red. Color images are available online.

from immature cartilage treated with either TGFβ1 or BMP9 revealed profound differences in collagen and cellular organization (Fig. 7). TGFβ1-treated pellets displayed characteristic parallel arrays of collagen alignment that extended from the periphery deep into the pellet, whereas BMP9-treated pellets displayed an anisotropic organization typically found in mature cartilage. Columnar arrays of collagen fibrils perpendicular to the surface zone were present in the deeper zones of BMP9-treated pellets and

chondrocytes were aligned in the direction of these fibrils (arrowed in Fig. 7).

Discussion

The results of this study demonstrate that BMP9 is a potent chondrogenic factor for immature articular cartilage-derived chondroprogenitors. PLM also reveals that BMP9 is capable of inducing morphological changes either by




FIG. 7. Organization of collagen fibrils in pellet cultures of freshly isolated full depth immature chondrocytes. Pellets composed of 1×10^5 cells each were cultured in standard chondrogenic medium for 21 days with either TGF β 1 (10 ng/mL) or BMP9 (100 ng/mL). Pellets were processed to wax, sectioned, and stained with hematoxylin and eosin (*upper panel*), safranin-O (*middle panel*), and PSR (*lower panel*). Scale bar equals 100 μ m. PSR-stained sections were visualized using polarized light microscopy and the bulk orientation of collagen fibrils is shown by the *arrows* in each image (*lower panels*). Representative images from three independent experiments. Color images are available online.

stimulating deposition or reconfiguration of extracellular matrices to produce an anisotropic structure that mirrors that seen during postnatal maturation [30,44]. This study was motivated by observations that articular cartilage-derived chondroprogenitors are incompletely differentiated in pellet culture when stimulated with TGF β 1 [26]. In selecting candidates for screening progenitors for enhanced chondrogenesis, we examined previous literature identifying chondrogenic factors for embryonic chick limb mesenchyme. Our reasoning for this approach was that chondroprogenitors used in this study were derived from newborn bovine cartilage whose structural organization is isotropic [23,24], therefore, it was likely that they would be more receptive to factors known to act on immature mesenchymal progenitors. Of particular note, we chose to include BMP9 (also known as growth and differentiation factor-2, GDF2) based on studies showing that it could induce chondrogenesis and phylogenetic data classifying it and BMP10 into a separate group from other BMPs [45]. The concentrations of chondrogenic factors used in this study were based on previously published data using identical or similar cells, an inherent limitation of this approach therefore is the possibility that some factors may not be present at their optimal concentration.

Following pellet culture for 21 days with candidate chondrogenic factors, BMP9 was the most potent as viewed by toluidine blue staining of sectioned tissue. Biochemical and gene expression analyses confirmed histological observations of BMP9 enhancing differentiation of chondroprogenitors especially when compared to growth factors TGF β 1–3. Of particular note was immunohistochemical data that showed the distribution of proteoglycan aggrecan, and collagen type II antibody labeling was evenly spread in BMP9 and db-cAMP compared to TGF β 1-treated pellets. We also observed a strong negative association between cellular proliferation and sGAG deposition, where BMP9-treated pellets did not show appreciable increase in cell number from initial seeding. Without monitoring cell death or proliferation directly, it is not possible to eliminate the possibility that there was a balance between cell death and proliferation within BMP9 pellets.

Analysis of gene expression of PCNA in BMP9-treated pellets over a period of 14 days showed that there was a peak in expression at day 7 and this coincided with a peak in expression of nestin transcripts. Nestin is a class VI intermediate filament protein that forms complex heterodimers and heterotetramers, and there is strong evidence in MSCs implicating it as a marker for multilineage progenitor cells [46]. Nestin expression identifies MSC subpopulations essential for hematopoietic stem cell expansion in the bone marrow niche [47], and a study by Kang et al. examining the role of IL6 in MSC cartilage differentiation showed that nestin antibody labeling colocalizes with MSC marker CD166 in macroscopically normal cartilage [48]. Therefore, based on these indirect observations, we predict that a subpopulation of chondroprogenitors are maintained within the growing cartilage pellet and may act as a reserve progenitor pool to stimulate further growth or repair [22,49,50].

Several reasons may explain why BMP9 is more effective than the other factors used in this study. Pulse-chase experiments using 35 S-sulfate and 3 H-proline by Hills et al. showed that intact juvenile (1- to 3-month-old) bovine cartilage explants treated with BMP9 increase their synthesis of proteoglycan and collagen extracellular matrix components and simultaneously exhibit reduced turnover of labeled proteins [51]. Decreased proteolysis of extracellular matrix mediated by BMP9 could be accomplished through suppression of protease activity by transcriptional mechanisms or indirectly through upregulation of tissue inhibitor of metalloproteinase gene transcription [52,53]. Conversely, the addition BMP9 (and BMP2) can overcome the inhibitory effect of physiologically relevant levels of proinflammatory cytokine IL1 β on bone marrow-derived MSC chondrogenesis by maintaining gene expression of COL2A1, ACAN, and SOX9 [39].

BMP2 preferentially binds to activin receptor-like kinase-3 and -4 (ALK3/4) receptors and this probably accounts for the differential induction of chondrogenesis in progenitors when compared to BMP9, as BMP9 ligands signal through ALK1/2 receptors as shown by inhibition of *in vitro* osteogenesis and *in vivo* ectopic bone formation following transfection of dominant-negative ALK receptors into bone-derived MSCs [54,55]. There is also evidence to suggest that BMP signaling predominates in the earliest stages of differentiation. Dedifferentiated articular chondrocytes cultured as pellets initially display higher BMP4 expression,

SMAD 1/5/8 phosphorylation, and SOX9 protein levels and undergo faster redifferentiation when compared to bone marrow-derived MSCs, highlighting the early role of BMPs in chondrogenesis [56]. Furthermore, transgenic studies conclude that TGF β growth factors are not essential for prechondrogenic condensation formation; conditional ablation of ALK5 using Dermo-Cre targeting mesenchymal progenitors does not affect either condensation or cartilage formation [57], indicating that stimulation of chondrogenesis through activation of SMAD 1/5/8 predominates in the early stages of differentiation.

During postnatal growth and homeostasis, TGF β signaling through ALK5 receptors act as an inhibitory stimulus on chondrocyte terminal differentiation and the adoption of a mineralizing phenotype in cells [58]. An age-associated imbalance in the ratio of ALK5 to ALK1 seen in osteoarthritic cartilage is also further evidence for the developmental and pathological context-dependent activities of BMP and TGF β growth factors on chondrocytes [59]. Therefore, articular chondroprogenitors may be primed to undergo rapid chondrogenic differentiation following receptor-mediated SMAD 1/5/8 signaling and, in later stages, postcondensation, TGF β -dependent SMAD 2/3 signaling may predominate to promote homeostatic growth and prevent mineralization in permanent chondrocytes.

PLM of cartilage pellets showed that for the most part, collagen fibrils were organized in highly fibrillar, annular, and concentric patterns. The exception were db-cAMP-treated pellets, where very weak birefringence signal was detected, indicating an unusual lack of fibril organization. In BMP9-treated pellets, there was evidence of fibrils organized perpendicular to the surface, but the birefringence signal was relatively weak (Fig. 6A, BMP9 inset). We hypothesized that the incomplete morphogenic effects of BMP9 on chondroprogenitors were due to the need for these cells first to undergo differentiation. Therefore, we cultured freshly isolated full-depth chondrocytes from immature cartilage with TGF β 1 and BMP9 for 21 days. BMP9-treated chondrocytes produced a birefringence pattern of collagen fibril alignment and organization indistinguishable from the pattern found in mature adult cartilage, with a thin ring of parallel fibers running across the peripheral boundary of the pellet below, which were fibers in antiparallel orientation. Chondrocytes in columnar organization and with enlarged chondrons were clearly visible in safranin O-stained sections of BMP9-treated pellets. In contrast, TGF β 1-treated chondrocyte pellets produced a broad fibrillar ring of collagen orientated parallel to the surface. AFM analysis of chondroprogenitors differentiated with TGF β 1 or BMP9 showed that TGF β 1-induced matrix deposition was predominantly fibrillar and significantly stiffer compared to BMP9-treated cells, which themselves produced a less fibrillar and more compliant matrix. Substrate compliance is known to alter not only cell phenotype but also plays a role in tissue development, where stiffer artificial matrices negatively regulate tissue architecture and differentiation [60].

We have previously proposed that a transient genetic program is activated to initiate postnatal maturation of articular cartilage [30–32], although it remains to be seen whether elements of this program have been invoked by BMP9 treatment. Also, in this study, we used progenitors and chondrocytes from immature cartilage and whether

progenitors and chondrocytes from older structurally mature cartilage are similarly receptive to BMP9-induced chondrogenesis or morphogenic cues also remains to be tested. Understanding how articular cartilage undergoes the postnatal transition from isotropically organized immature cartilage to anisotropically mature cartilage is critical for tissue engineering, regeneration, and repair strategies. Whether chondroprogenitor proliferation at the joint surface initiates a process of appositional growth generating trailing pillars or stacks of daughter cells [24,61] or cellular hypertrophy, matrix deposition, and reorganization of chondrocytes underlies the growth and maturation of the tissue [62] are issues that need to be resolved. Our finding showing for the first time that postnatal maturation can be rapidly recapitulated in vitro may help to shed light on these competing hypotheses.

In conclusion, BMP9 is a potent chondrogenic factor for immature chondroprogenitors and additionally provides morphogenic cues for progenitors and differentiated chondrocytes to generate adult-like anisotropic organization. The identification of BMP9 opens up the possibility of using allogeneic culture-expanded progenitors for in vitro production of fully differentiated and functional implants for repair of localized cartilage lesions.

Acknowledgment

The authors gratefully acknowledge Julie Thomas (Cig Calon Cymru, Llanelli, UK) for the provision of study materials.

Author Disclosure Statement

All the authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this article.

Funding Information

The authors gratefully acknowledge funding received from the UK Regenerative Medicine Platform (UK RMP MRL02280X/1), Versus Arthritis (UK), and Reumafonds (the Netherlands).

References

1. Chen FH, KT Rousche and RS Tuan. (2006). Technology insight: adult stem cells in cartilage regeneration and tissue engineering. *Nat Clin Pract Rheumatol* 2:373–382.
2. Danisovic L, I Varga and S Polak. (2012). Growth factors and chondrogenic differentiation of mesenchymal stem cells. *Tissue Cell* 44:69–73.
3. De Bari C and AJ Roelofs. (2018). Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. *Curr Opin Pharmacol* 40:74–80.
4. Aroen A, S Loken, S Heir, E Alvik, A Ekeland, OG Granlund and L Engebretsen. (2004). Articular cartilage lesions in 993 consecutive knee arthroscopies. *Am J Sports Med* 32:211–215.
5. Davies-Tuck ML, AE Wluka, Y Wang, AJ Teichtahl, G Jones, C Ding and FM Cicuttini. (2008). The natural history

- of cartilage defects in people with knee osteoarthritis. *Osteoarthritis Cartilage* 16:337–342.
6. Hunziker EB. (2002). Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. *Osteoarthritis Cartilage* 10:432–463.
 7. Morales TL. (2007). Chondrocyte moves: clever strategies? *Osteoarthritis Cartilage* 15:861–871.
 8. Steadman JR, WG Rodkey, KK Briggs and JJ Rodrigo. (1999). The microfracture technic in the management of complete cartilage defects in the knee joint [in German]. *Orthopade* 28:26–32.
 9. Brittberg M, A Lindahl, A Nilsson, C Ohlsson, O Isaksson and L Peterson. (1994). Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 331:889–895.
 10. Hunziker EB, K Lippuner, MJ Keel and N Shintani. (2015). An educational review of cartilage repair: precepts & practice—myths & misconceptions—progress & prospects. *Osteoarthritis Cartilage* 23:334–350.
 11. Knutsen G, JO Drogset, L Engebretsen, T Grontvedt, TC Ludvigsen, S Loken, E Solheim, T Strand and O Johansen. (2016). A randomized multicenter trial comparing autologous chondrocyte implantation with microfracture: long-term follow-up at 14 to 15 years. *J Bone Joint Surg Am* 98:1332–1339.
 12. Gross AE, EA Silverstein, J Falk, R Falk and F Langer. (1975). The allotransplantation of partial joints in the treatment of osteoarthritis of the knee. *Clin Orthop Relat Res* 7–14.
 13. Chahal J, AE Gross, C Gross, N Mall, T Dwyer, A Chahal, DB Whelan and BJ Cole. (2013). Outcomes of osteochondral allograft transplantation in the knee. *Arthroscopy* 29:575–588.
 14. Gross AE, N Shasha and P Aubin. (2005). Long-term followup of the use of fresh osteochondral allografts for posttraumatic knee defects. *Clin Orthop Relat Res* 79–87.
 15. Pallante AL, WC Bae, AC Chen, S Gortz, WD Bugbee and RL Sah. (2009). Chondrocyte viability is higher after prolonged storage at 37 degrees C than at 4 degrees C for osteochondral grafts. *Am J Sports Med* 37(Suppl 1):24S–32S.
 16. Benya PD and JD Shaffer. (1982). Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. *Cell* 30:215–224.
 17. Foldager CB, AH Gomoll, M Lind and M Spector. (2012). Cell seeding densities in autologous chondrocyte implantation techniques for cartilage repair. *Cartilage* 3:108–117.
 18. Wakitani S, T Goto, SJ Pineda, RG Young, JM Mansour, AI Caplan and VM Goldberg. (1994). Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 76:579–592.
 19. Johnstone B and JU Yoo. (1999). Autologous mesenchymal progenitor cells in articular cartilage repair. *Clin Orthop Relat Res* S156–S162.
 20. de Windt TS, LA Vonk, IC Slaper-Cortenbach, MP van den Broek, R Nizak, MH van Rijen, RA de Weger, WJ Dhert and DB Saris. (2017). Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-stage cartilage repair in humans upon mixture with recycled autologous chondrons. *Stem Cells* 35:256–264.
 21. Baraniak PR and TC McDevitt. (2010). Stem cell paracrine actions and tissue regeneration. *Regen Med* 5:121–143.
 22. Alsalameh S, R Amin, T Gemba and M Lotz. (2004). Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis Rheum* 50:1522–1532.
 23. Dowthwaite GP, JC Bishop, SN Redman, IM Khan, P Rooney, DJ Evans, L Houghton, Z Bayram, S Boyer, et al. (2004). The surface of articular cartilage contains a progenitor cell population. *J Cell Sci* 117:889–897.
 24. Kozhemyakina E, M Zhang, A Ionescu, UM Ayturk, N Ono, A Kobayashi, H Kronenberg, ML Warman and AB Lassar. (2015). Identification of a Prg4-expressing articular cartilage progenitor cell population in mice. *Arthritis Rheumatol* 67:1261–1273.
 25. Williams R, IM Khan, K Richardson, L Nelson, HE McCarthy, T Analbelsi, SK Singhrao, GP Dowthwaite, RE Jones, et al. (2010). Identification and clonal characterisation of a progenitor cell sub-population in normal human articular cartilage. *PLoS One* 5:e13246.
 26. Khan IM, JC Bishop, S Gilbert and CW Archer. (2009). Clonal chondroprogenitors maintain telomerase activity and Sox9 expression during extended monolayer culture and retain chondrogenic potential. *Osteoarthritis Cartilage* 17:518–528.
 27. McCarthy HE, JJ Bara, K Brakspear, SK Singhrao and CW Archer. (2012). The comparison of equine articular cartilage progenitor cells and bone marrow-derived stromal cells as potential cell sources for cartilage repair in the horse. *Vet J* 192:345–351.
 28. Johnstone B, TM Hering, AI Caplan, VM Goldberg and JU Yoo. (1998). In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* 238:265–272.
 29. Penick KJ, LA Solchaga and JF Welter. (2005). High-throughput aggregate culture system to assess the chondrogenic potential of mesenchymal stem cells. *Biotechniques* 39:687–691.
 30. Khan IM, SL Evans, RD Young, EJ Blain, AJ Quantock, N Avery and CW Archer. (2011). Fibroblast growth factor 2 and transforming growth factor beta1 induce precocious maturation of articular cartilage. *Arthritis Rheum* 63:3417–3427.
 31. Khan IM, L Francis, PS Theobald, S Perni, RD Young, P Prokopovich, RS Conlan and CW Archer. (2013). In vitro growth factor-induced bio engineering of mature articular cartilage. *Biomaterials* 34:1478–1487.
 32. Zhang Y, BJ Morgan, R Smith, CR Fellows, C Thornton, M Snow, LW Francis and IM Khan. (2017). Platelet-rich plasma induces post-natal maturation of immature articular cartilage and correlates with LOXL1 activation. *Sci Rep* 7:3699.
 33. Kim YJ, RL Sah, JY Doong and AJ Grodzinsky. (1988). Fluorometric assay of DNA in cartilage explants using Hoechst 33258. *Anal Biochem* 174:168–176.
 34. Hoffman LM and WM Kulyk. (1999). Alcohol promotes in vitro chondrogenesis in embryonic facial mesenchyme. *Int J Dev Biol* 43:167–174.
 35. Krejci P, B Masri, V Fontaine, PB Mekikian, M Weis, H Prats and WR Wilcox. (2005). Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. *J Cell Sci* 118:5089–5100.
 36. Kulyk WM and C Reichert. (1992). Staurosporine, a protein kinase inhibitor, stimulates cartilage differentiation by embryonic facial mesenchyme. *J Craniofac Genet Dev Biol* 12:90–97.
 37. Kulyk WM, BJ Rodgers, K Greer and RA Kosher. (1989). Promotion of embryonic chick limb cartilage differentiation by transforming growth factor-beta. *Dev Biol* 135:424–430.

38. Lee YS and CM Chuong. (1997). Activation of protein kinase A is a pivotal step involved in both BMP-2- and cyclic AMP-induced chondrogenesis. *J Cell Physiol* 170:153–165.
39. Majumdar MK, E Wang and EA Morris. (2001). BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1. *J Cell Physiol* 189:275–284.
40. Matsutani E and Y Kuroda. (1982). Effect of lectins on chondrogenesis of cultured quail limb bud cells. *Dev Biol* 89:521–526.
41. Morales TI and AB Roberts. (1988). Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. *J Biol Chem* 263:12828–12831.
42. Quarto R, G Campanile, R Cancedda and B Dozin. (1992). Thyroid hormone, insulin, and glucocorticoids are sufficient to support chondrocyte differentiation to hypertrophy: a serum-free analysis. *J Cell Biol* 119:989–995.
43. Rodgers BJ, WM Kulyk and RA Kosher. (1989). Stimulation of limb cartilage differentiation by cyclic AMP is dependent on cell density. *Cell Differ Dev* 28:179–187.
44. Hunziker EB, E Kapfinger and J Geiss. (2007). The structural architecture of adult mammalian articular cartilage evolves by a synchronized process of tissue resorption and neoformation during postnatal development. *Osteoarthritis Cartilage* 15:403–413.
45. Chatterjee S, M Haque, MS Rahman, HM Jamil, N Akhtar, SM Abdul-Awal, MS Rahman and SM Asaduzzaman. (2017). Conservation pattern, homology modeling and molecular phylogenetic study of BMP ligands. *Trends Bioinform* 9:70–80.
46. Wiese C, A Rolletschek, G Kania, P Blyszczuk, KV Tarasov, Y Tarasova, RP Wersto, KR Boheler and AM Wobus. (2004). Nestin expression—a property of multi-lineage progenitor cells? *Cell Mol Life Sci* 61:2510–2522.
47. Mendez-Ferrer S, TV Michurina, F Ferraro, AR Mazloom, BD Macarthur, SA Lira, DT Scadden, A Ma'ayan, GN Enikolopov and PS Frenette. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 466:829–834.
48. Kang Q, MH Sun, H Cheng, Y Peng, AG Montag, AT Deyrup, W Jiang, HH Luu, J Luo, et al. (2004). Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. *Gene Ther* 11:1312–1320.
49. Kondo M, K Yamaoka, K Sakata, K Sonomoto, L Lin, K Nakano and Y Tanaka. (2015). Contribution of the interleukin-6/STAT-3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells. *Arthritis Rheumatol* 67:1250–1260.
50. Pretzel D, S Linss, S Rochler, M Endres, C Kaps, S Alsalameh and RW Kinne. (2011). Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage. *Arthritis Res Ther* 13:R64.
51. Hills RL, LM Belanger and EA Morris. (2005). Bone morphogenetic protein 9 is a potent anabolic factor for juvenile bovine cartilage, but not adult cartilage. *J Orthop Res* 23:611–617.
52. Fukui T, T Suga, RH Iida, M Morito, X Luan, TG Diekwisch, Y Nakamura and A Yamane. (2010). BMP-2 regulates the formation of oral sulcus in mouse tongue by altering the balance between TIMP-1 and MMP-13. *Anat Rec (Hoboken)* 293:1408–1415.
53. Badlani N, Y Oshima, R Healey, R Coutts and D Amiel. (2009). Use of bone morphogenetic protein-7 as a treatment for osteoarthritis. *Clin Orthop Relat Res* 467:3221–3229.
54. Miyazono K, Y Kamiya and M Morikawa. (2010). Bone morphogenetic protein receptors and signal transduction. *J Biochem* 147:35–51.
55. Luo J, M Tang, J Huang, BC He, JL Gao, L Chen, GW Zuo, W Zhang, Q Luo, et al. (2010). TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. *J Biol Chem* 285:29588–29598.
56. Dexheimer V, J Gabler, K Bomans, T Sims, G Omlor and W Richter. (2016). Differential expression of TGF-beta superfamily members and role of Smad1/5/9-signalling in chondral versus endochondral chondrocyte differentiation. *Sci Rep* 6:36655.
57. Matsunobu T, K Torigoe, M Ishikawa, S de Vega, AB Kulkarni, Y Iwamoto and Y Yamada. (2009). Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. *Dev Biol* 332:325–338.
58. van der Kraan PM, EN Blaney Davidson, A Blom and WB van den Berg. (2009). TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. *Osteoarthritis Cartilage* 17:1539–1545.
59. Blaney Davidson EN, DF Remst, EL Vitters, HM van Beuningen, AB Blom, MJ Goumans, WB van den Berg and PM van der Kraan. (2009). Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. *J Immunol* 182:7937–7945.
60. Peters SB, N Naim, DA Nelson, AP Mosier, NC Cady and M Larsen. (2014). Biocompatible tissue scaffold compliance promotes salivary gland morphogenesis and differentiation. *Tissue Eng Part A* 20:1632–1642.
61. Li L, PT Newton, T Boudierlique, M Sejnohova, T Zikmund, E Kozhemyakina, M Xie, J Krivanek, J Kaiser, et al. (2017). Superficial cells are self-renewing chondrocyte progenitors, which form the articular cartilage in juvenile mice. *FASEB J* 31:1067–1084.
62. Decker RS, HB Um, NA Dymont, N Cottingham, Y Usami, M Enomoto-Iwamoto, MS Kronenberg, P Maye, DW Rowe, E Koyama and M Pacifici. (2017). Cell origin, volume and arrangement are drivers of articular cartilage formation, morphogenesis and response to injury in mouse limbs. *Dev Biol* 426:56–68.

Address correspondence to:

Dr. Ilyas M. Khan
Centre of Nanohealth
Swansea University Medical School
Singleton Park
Swansea SA2 8PP
Wales
United Kingdom

E-mail: i.m.khan@swan.ac.uk

Received for publication September 17, 2019

Accepted after revision May 1, 2020

Prepublished on Liebert Instant Online May 1, 2020